Among sequence variant changes, 18.2% of MPN cases were positive for <i>BCR::ABL1</i>, 8.5% for <i>JAK-2</i> p.V617F, 0.5% for <i>CALR</i>, 0.04% for <i>MPL</i>, and none for <i>JAK-2</i> exon 12. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.